| It is an antineoplastic and immuno modulating agent. It is bio-transformed in liver to active alkylated metabolite. These metabolites interfere with growth of susceptible rapidly multiplying malignant cells by cross-linking of tumour cell-DNA
| Indications : | Hodgekin's disease, lymphocytic lymphogranulomatosis, chronic lymphocytic leukaemia, acute lymphoblastic leukemia, mycosis, adenocarcinoma ovary, carcinoma breast. Also useful in biopsy diagonsed minimal change nephrotic syndrome in children who fail to respond to steroids. | | Contraindications : | Pregnancy, lactation | | Safety Profile : | Regular haematological profile and urine examination should be done. | | Adverse Effects : | Sterility in both sexes may occur, amenorrhoea, haemorrhagic cystitis, fibrosis of bladder, nausea, vomitting, anorexia, alopecia, skin rash, pigmentation, leucopenia, thrombocytopenia, intestinal pulmonary fibrosis, anaphylactic reactions. | | Dosage : | In malignant disease : Adult & Children - Initial course 40-50 mg/kg i.v. in divided dose over 2-5 days or 10-15 mg/kg i.v. given every 7-10 days Oral- 1-5 mg/kg/day for both sexes and maintenance phase. In combination cytotoxic regimen, it may be necessary to decrease the dose. In minimal change disease in children oral; 2.5 to 3mg./kg/day for 60-90 days. | | Purity : | Not less than 99%. |
|
 |
© Health Biotech Limited. All Rights Reserved (Terms of Use)